BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?

First Live Meeting Since 2019 Begins In San Diego

14 Jun 2022

• By Scrip Team

News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.

BIO 2022 Notebook Day 1 — • Source: Shutterstock

The annual BIO International Convention finally resumed in person on 13 June in San Diego after COVID-19 kept the industry from meeting face-to-face in 2020 and 2021 – but the conference comes at a tumultuous time for biopharmaceutical companies. The convention, a prime venue for partnering discussions, may be occurring just in time for firms that could benefit from some collaboration cash while other financing sources may be elusive.

Turbulent trading in the stock market mainly due to macroeconomic concerns – rising inflation, shrinking inventories and the war in...